找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Immunotherapy Against Lung Cancer; Emerging Opportuniti Shvetank Bhatt,Rajaraman Eri Eri,Kamal Dua Book 2024 The Editor(s) (if applicable)

[复制链接]
楼主: 驼峰
发表于 2025-3-30 09:16:11 | 显示全部楼层
发表于 2025-3-30 14:11:27 | 显示全部楼层
发表于 2025-3-30 17:28:51 | 显示全部楼层
发表于 2025-3-30 22:56:30 | 显示全部楼层
发表于 2025-3-31 03:20:09 | 显示全部楼层
发表于 2025-3-31 06:25:32 | 显示全部楼层
Introduction to Lung Cancer,s a key risk factor for the disease. Small-cell carcinomas and non-small-cell carcinomas are the two types of lung cancer that may be generically categorised. Up to 75% of lung cancer cases are non-small-cell lung cancer (NSCLC), which is more prevalent. Chest radiography, sputum cytology, bronchosc
发表于 2025-3-31 12:49:43 | 显示全部楼层
Immunobiology of Lung Cancer,rapy are likely to blame. A number of important immune cells, including as CD4+ and CD8+ T-lymphocytes, macrophages, dendritic cells, and natural killer cells, are involved in the pathogenesis of lung cancer. Growing knowledge about these cells points to a highly intricate and interconnected network
发表于 2025-3-31 15:36:00 | 显示全部楼层
Evolution of Lung Cancer Treatment from Classical Chemotherapy to Advanced Immunotherapy,n-small-cell lung cancer (NSCLC) is 28% and small-cell lung cancer (SCLC) is 7%. The standard care of treatment for such a deadly disease includes surgery, radiation therapy, and chemotherapy. Among these, chemotherapy is a painless treatment procedure that uses chemically formulated drugs and bioti
发表于 2025-3-31 18:01:16 | 显示全部楼层
发表于 2025-3-31 22:23:24 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-23 16:26
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表